Literature DB >> 12835708

HIV vaccines 1983-2003.

Andrew J McMichael1, Tomas Hanke.   

Abstract

Twenty years after the discovery of HIV, there is still no vaccine. This year, an envelope vaccine aimed at stimulating neutralizing antibodies was unable to protect against infection in phase 3 trials. But more than 20 HIV vaccines designed to stimulate T-cell responses are being developed. Will any of them work?

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12835708     DOI： 10.1038/nm0703-874

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


  78 in total

1.  Blocking the docking of HIV-1.

Authors:  Aine McKnight; Robin A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-08       Impact factor: 11.205

Review 2.  Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections.

Authors:  Maurice R Hilleman
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

3.  Consequences of cytotoxic T-lymphocyte escape: common escape mutations in simian immunodeficiency virus are poorly recognized in naive hosts.

Authors:  Thomas C Friedrich; Adrian B McDermott; Matthew R Reynolds; Shari Piaskowski; Sarah Fuenger; Ivna P De Souza; Richard Rudersdorf; Candice Cullen; Levi J Yant; Lara Vojnov; Jason Stephany; Sarah Martin; David H O'Connor; Nancy Wilson; David I Watkins
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

4.  A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

5.  Development of an AIDS vaccine: a daunting epidemiological challenge.

Authors:  Neal Nathanson; Bonnie J Mathieson
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

6.  Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.

Authors:  Miki Kawada; Hiroko Igarashi; Akiko Takeda; Tetsuo Tsukamoto; Hiroyuki Yamamoto; Sachi Dohki; Masafumi Takiguchi; Tetsuro Matano
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

7.  Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice.

Authors:  Jianping Lin; Yan Zhi; Lauren Mays; James M Wilson
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

8.  Reversion in vivo after inoculation of a molecular proviral DNA clone of simian immunodeficiency virus with a cytotoxic-T-lymphocyte escape mutation.

Authors:  Masahiro Kobayashi; Hiroko Igarashi; Akiko Takeda; Moriaki Kato; Tetsuro Matano
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

Review 9.  Novel humanized murine models for HIV research.

Authors:  Paul W Denton; J Victor Garcia
Journal:  Curr HIV/AIDS Rep       Date:  2009-02       Impact factor: 5.071

10.  Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial.

Authors:  Miki Kawada; Tetsuo Tsukamoto; Hiroyuki Yamamoto; Nami Iwamoto; Kyoko Kurihara; Akiko Takeda; Chikaya Moriya; Hiroaki Takeuchi; Hirofumi Akari; Tetsuro Matano
Journal:  J Virol       Date:  2008-07-30       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.